Skip to main content
. Author manuscript; available in PMC: 2022 Oct 15.
Published in final edited form as: Cancer Res. 2022 Apr 15;82(8):1534–1547. doi: 10.1158/0008-5472.CAN-20-0821

Figure 1: A genome-wide CRISPR-Cas9 screen identifies mediators of erlotinib resistance.

Figure 1:

A) Outline of the screen. B) Fold enrichment (β-score) analysis of sgRNAs. Blue: genes previously been reported to be downregulated in cells post chemotherapeutic treatment; red: genes reported to be high in erlotinib sensitive cells; green genes reported as tumor suppressors.